Literature DB >> 20424570

The cardiovascular burden of end-stage renal disease patients.

G Cianciolo1, G Donati, G La Manna, A Ferri, V Cuna, G Ubaldi, S Corsini, N Lanci, L Colì, S Stefoni.   

Abstract

Patients with end-stage renal disease are 10 to 20 times more at risk of cardiovascular death than the general population. Traditional cardiovascular risk factors are not able to explain the increase in the onset of cardiovascular diseases in dialysis patients. Some of the most important non traditional risk factors in uremic patients are: the inflammatory state of the patients, cytokines and growth factors, hyperhomocysteinemia, the presence of alterations of the calcium phosphorous product which can already be in progress when the glomerular filtration rate decreases to less than 60 mL/min. Clinically, these alterations cause vascular calcifications, calcifications of the heart valves and calcific uremic arteriolopathy or calciphylaxis. The pathogenesis of vascular calcification is complex and cannot be assigned to a simple, passive process: in fact, it includes factors which promote or inhibit calcification. In turn, these pathologic conditions have been found to be highly predictive of general and cardiovascular death. Given the serious clinical consequences that vascular calcifications can cause, it is necessary to carry out an early mapping of the traditional and non traditional risk factors of uremic patients as it seems that therapeutic interventions aimed at reducing or inverting the calcification process can improve the outcome of patients, above all when they are started quickly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20424570

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  6 in total

Review 1.  [Cutaneous calciphylaxis].

Authors:  U Wollina
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

2.  Efficacy of Supra-HFR in Removing FGF23 and Cytokines: A Single Session Analysis.

Authors:  Gabriele Donati; Andrea Angeletti; Maria Cappuccilli; Chiara Donadei; Chiara Guglielmo; Anna Scrivo; Lorenzo Gasperoni; Maddalena Zambelli; Maria Mattiotti; Gaetano La Manna
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

Review 3.  The Role of Gut-Derived, Protein-Bound Uremic Toxins in the Cardiovascular Complications of Acute Kidney Injury.

Authors:  Pauline Caillard; Youssef Bennis; Isabelle Six; Sandra Bodeau; Saïd Kamel; Gabriel Choukroun; Julien Maizel; Dimitri Titeca-Beauport
Journal:  Toxins (Basel)       Date:  2022-05-11       Impact factor: 5.075

4.  Vascular Adventitia Calcification and Its Underlying Mechanism.

Authors:  Na Li; Wenli Cheng; Tiequn Huang; Jie Yuan; Xi Wang; Meiyue Song
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

5.  An in vitro model of renal inflammation after ischemic oxidative stress injury: nephroprotective effects of a hyaluronan ester with butyric acid on mesangial cells.

Authors:  Olga Baraldi; Francesca Bianchi; Viola Menghi; Andrea Angeletti; Anna Laura Croci Chiocchini; Maria Cappuccilli; Valeria Aiello; Giorgia Comai; Gaetano La Manna
Journal:  J Inflamm Res       Date:  2017-09-08

Review 6.  Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First?

Authors:  Giuseppe Cianciolo; Antonio De Pascalis; Luca Di Lullo; Claudio Ronco; Chiara Zannini; Gaetano La Manna
Journal:  Cardiorenal Med       Date:  2017-06-21       Impact factor: 2.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.